Regenerative Medicine News

January 12, 2017 – (TSRI) – “This cellular clock needs to be finely tuned to allow sufficient cell divisions to develop differentiated tissues and maintain renewable tissues in our body and, at the same time, to limit the proliferation of cancerous cells," said TSRI Associate Professor Eros Lazzerini Denchi, corresponding author of the new study.
January 9, 2017 – (Promothera) – “This alliance represents a great opportunity for Promethera to shape the global commercialization strategy for our novel cell-based therapeutics. Even more importantly, the partnership offers us a way to benefit from the positive environment for such cutting-edge therapies and regenerative medicine in Korea and to drive the development of our novel platforms in this key market,” said Dr. John Tchelingerian, CEO of Promethera Biosciences. 
January 19, 2017 – (Abeona) – “This designation builds on our commercial portfolio of AAV gene therapies that have received FDA and EMA orphan drug designations, which is an important validation of the scientific and clinical translation of these products for severely underserved patient populations,” stated Timothy J. Miller, Ph.D., President & CEO of Abeona Therapeutics Inc. 
January 19, 2017 – (Cytori) – “Azaya’s technology and intellectual property present an exciting opportunity to marry Cytori’s cell therapy technology, which is currently in late-stage clinical trials, to a clinically proven and patented off-the-shelf pharmaceutical delivery system directly applicable to regenerative medicine,” said Marc H. Hedrick, M.D., President and Chief Executive Officer of Cytori.
pornpornpornoA playback is now available of ARM's webinar "Understanding the 21st Century Cures Act for Cell & Gene Therapies" held on February 2 with representatives from FDA. Visit the webpage and access the playback.
January 18, 2017 – (Athersys) – Under the terms of the agreement, ReGenesys will receive an initial payment in exchange for an exclusive period to evaluate the cell therapy technology with an option to negotiate for a license for the development and commercialization of the technology for this area.
January 18, 2017 – (Invetech) – New suite of customized equipment is intended to enable scalable, cost-effective GMP manufacturing of Erytech’s proprietary therapeutic product candidates based on its ERYCAPS platform.